Our Pipeline

Neumora has rapidly scaled our therapeutic pipeline through both business development activities and internal discovery capabilities. Our therapeutic pipeline is comprised of seven programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action.

Our lead program, navacaprant, is a highly selective, novel kappa opioid receptor (KOR) antagonist in Phase 3 development as a potential monotherapy treatment for MDD. Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways, which play an important role in the regulation of mood, cognition, reward, and behavior. The KOR system is a well-characterized pathway known to mediate depressive-like states, and modulating this system represents a novel approach to treating MDD and other major neuropsychiatric disorders.

navacaprant key references